Summarized by Masters of Longevity from Longevity Technology.
A preview of a biotech news article describing an upcoming Phase II Alzheimer’s vaccine trial presentation and study design being shared at CTAD, inviting readers curious about new clinical development approaches in the field.
Key Takeaways
- Alzinova will present the Phase II ADVANCE trial design for vaccine candidate ALZ-101 at CTAD and in a journal abstract.
- ADVANCE is a randomized, double-blind, placebo-controlled Phase IIa study measuring therapeutic effect, not just safety.
- Worldwide Clinical Trials is supporting operations and first participant enrollment is expected around late 2026 to early 2027.
